targedbiopharmaceuticals.com
TGD001 Our Science & Innovation Therapeutic Areas Development Pipeline Scientific Publications What is TGD001? TGD001 is TargED’s innovative therapy in development for targeted clot breakdown: thrombolysis, localized at the site of thrombosis.
No named decision-maker yet.
No careers mailbox known
2020
Founded
First-in-class ADCs tailored to attack advanced cancer.. Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer.
No named decision-maker yet.
Careers mailbox is known
2019
Founded
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high unmet medical need.
No named decision-maker yet.
Careers mailbox is known
May 31, 2023
Certified Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy · minoryx.com
Nov 9, 2022
Partnership Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe · minoryx.com
May 30, 2022
Raised a round Venture round $55.1M
